Welcome to our dedicated page for Entera Bio SEC filings (Ticker: ENTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Entera Bio Ltd. (ENTX) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures as a NASDAQ-listed issuer. Entera Bio is a clinical-stage biopharmaceutical company organized under the laws of Israel that develops oral peptide and protein replacement therapies using its proprietary N-Tab™ platform. Its filings with the U.S. Securities and Exchange Commission offer detailed information on clinical progress, regulatory interactions, financial position and material events.
Investors can review current reports on Form 8-K, which Entera Bio uses to announce significant developments such as FDA feedback on its EB613 Phase 3 study design, written agreements on nonclinical study requirements, and quarterly financial results. For example, recent 8-K filings describe FDA concurrence that a single 24‑month Phase 3 trial using total hip bone mineral density as the primary endpoint would support a New Drug Application for EB613, and outline the company’s financial results for specific quarters.
Over time, this page will also surface annual reports (Form 10-K or 20-F equivalents for foreign issuers), quarterly reports, and other registration or offering documents that Entera Bio files, where available in EDGAR. These filings typically discuss the company’s pipeline, including EB613 for osteoporosis, EB612 for hypoparathyroidism, and collaboration programs with OPKO Health for oral GLP-2 and oxyntomodulin tablet candidates.
Stock Titan enhances these documents with AI-powered summaries that explain the key points of lengthy filings, helping users quickly understand clinical milestones, regulatory updates, risk factors and capital structure details. Users can also monitor insider and related transaction disclosures when reported on forms such as Form 4, alongside other material events that may affect ENTX. With real-time updates from EDGAR and simplified explanations, this page is designed to make Entera Bio’s SEC reporting more accessible to both experienced and newer investors.